Maraviroc/cisplatin combination inhibits gastric cancer tumoroid growth and improves mice survival

Maraviroc/cisplatin combination inhibits gastric cancer tumoroid growth and improves mice survival

Abstract Background Gastric cancer (GC) is a significant cancer-related cause of death worldwide. GC’s most used chemotherapeutic regimen is based on platinum drugs such as cisplatin (CDDP). However, CDDP chemoresistance reduces the survival rate of advanced GC. The immune C-C chemokine receptor typ...

Full description

Saved in:
Bibliographic Details
Main Authors: Bárbara Mora-Lagos, María Elena Reyes, Lorena Lobos-Gonzalez, Matías del Campo, Kurt Buchegger, Louise Zanella, Ismael Riquelme, Carmen Gloria Ili, Priscilla Brebi
Format: Article
Language:English
Published: BMC 2025-01-01
Series:Biological Research
Subjects:
Gastric cancer (GC)
Cisplatin (CDDP)
Chemoresistance
C-C chemokine receptor type 5 (CCR5)
C-C motif chemokine ligand 5 (CCL5)
Maraviroc (MVC)
Online Access:https://doi.org/10.1186/s40659-024-00581-3
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://doi.org/10.1186/s40659-024-00581-3

Similar Items